Fortrea Holdings Inc. (FTRE)
NASDAQ: FTREHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
FTRE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.79B
- Forward P/E
- 16.52
- EPS (TTM)
- -$0.73
- Dividend yield
- None
- 52-week range
- 8.55 – 26.16
- Day range
- 18.30 – 20.52
- Volume / Avg
- 1.54M / 1.69M
- Beta
- —
- Shares outstanding
- 96.50M
52-week range
FTRE stock today
Fortrea (FTRE) closed at $18.55 on Nov 20, down 7.94% (-$1.60), versus the S&P 500's 3.70% decline. Shares are 29.1% below their 52-week high of $26.16, set on Oct 28, 2026 and 117.0% above the 52-week low of $8.55, in the middle of the past year's range. FTRE is up 7.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 70.2%.
Fortrea has posted a net loss over the last twelve months (EPS of -$0.73), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Fortrea
Company profileFortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Anshul Thakral
- Headquarters
- Durham, NC
- Employees
- 14,000
- Website
- fortrea.com
Financial highlights
Full financialsIn fiscal 2025, Fortrea generated $2.72 billion in revenue, up 1.0% from fiscal 2024. Fortrea reported a net loss of $986.2 million, compared with a loss of $328.5 million a year earlier. Gross margin was 18.5% (down from 19.8%) and operating margin -32.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.72B | $2.70B | $2.84B | $2.84B | $3.06B |
| Growth | +1.00% | -5.14% | +0.19% | -7.21% | — |
| Net income | $-986.20M | $-328.50M | $-25.20M | $186.20M | $98.00M |
| EPS (diluted) | $-10.81 | $-3.67 | $-0.29 | $2.09 | $1.10 |
Analyst forecast
ForecastConsensus (13 analysts)
buy
Avg. price target
$23.63+27.39%
- Strong buy 1
- Buy 6
- Hold 3
- Sell 1
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $0.01 vs $0.24
- Surprise
- -95.83%
FTRE news
All FTRE news- Fortrea (FTRE) Q3 2026 Earnings Call TranscriptNasdaq
- Fortrea Holdings Inc. Reports Third Quarter 2026 Financial Results and Updates Full-Year GuidanceNasdaq
- Fortrea Holdings Non-GAAP EPS of $0.28 beats by $0.06, revenue of $691.5M beats by $19.98MSeeking Alpha
- Fortrea Reports Third Quarter 2026 ResultsGlobeNewswire
- Fortrea to Participate in Jefferies Global Healthcare ConferenceGlobeNewswire
- Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?NasdaqVRTX, FTRE
- Fortrea 与 Omico 携手,推进生物标志物导向的肿瘤药物开发GlobeNewswire
- Fortrea 與 Omico 攜手合作,推動生物標記主導的腫瘤藥物開發GlobeNewswire
Fortrea peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CLOVClover Health Investments Corp. Class A | 3.73 | -1.06% | $2.00B | vs FTRE |
| VCYTVeracyte Inc. | 25.13 | +0.36% | $2.03B | vs FTRE |
| PSNLPersonalis Inc. | 14.27 | -3.06% | $1.55B | vs FTRE |
| TRUPTrupanion Inc. | 35.56 | -0.86% | $1.54B | vs FTRE |
| LMRILumexa Imaging Holdings Inc. | 14.26 | +1.42% | $1.37B | vs FTRE |
| ALHCAlignment Healthcare Inc. | 6.37 | -2.00% | $1.33B | vs FTRE |
| FRNMFreenome Inc. | 9.36 | -5.69% | $1.04B | vs FTRE |
| CSTLCastle Biosciences Inc. | 32.86 | -1.63% | $1.01B | vs FTRE |
Indexes, lists and sector
Fortrea stock FAQ
What is Fortrea's stock price today?
FTRE last traded at $18.55 as of Nov 20, 4:00 PM EST, down 7.94% on the day. Prices are delayed at least 15 minutes.
Who is Fortrea's CEO?
Mr. Anshul Thakral is the chief executive officer of Fortrea Holdings Inc., which has about 14,000 employees.
What is the FTRE 52-week high?
The 52-week high for FTRE is $26.16 and the 52-week low is $8.55. The stock is currently 29.1% below its high.